Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells

Molecular Pharmacology

Volumn 84, Issue 4, 2013, Pages 562-571

  Sajithlal, Gangadharan B ^a   Hamed, Hossein A ^a   Cruickshanks, Nichola ^a   Booth, Laurence ^a   Tavallai, Seyedmehrad ^a   Syed, Jahangir ^a   Grant, Steven ^a   Poklepovic, Andrew ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; BECLIN 1; CASPASE 3; CASPASE 8; CASPASE 9; GLYCOGEN SYNTHASE KINASE 3; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MICROTUBULE ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; REGORAFENIB; SORAFENIB; TENSIN; VASCULOTROPIN C;

ARTICLE; AUTOPHAGY; BRAIN CANCER; CANCER INHIBITION; CELL KILLING; CELL VIABILITY; COLON CANCER; HEPATOMA CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; THYMOMA;

ANIMALS; CELL COMMUNICATION; CELL DEATH; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GONANES; HEP G2 CELLS; HUMANS; MICE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; THYMOMA; THYMUS NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884688237     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.088005     Document Type: Article

References (30)

1. Alers S, Löffler AS, Wesselborg S, and Stork B (2012) Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 32:2-11.
2. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, and Burow ME et al. (2011) Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 71:4955-4967.
3. Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, and Kozikowski AP et al. (2005) Activated forms of H-RAS and KRAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 4: 257-270. (Pubitemid 40340205)
4. Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG, and Tafaro A (2013) Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 228:292-297.
5. Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, and Flaherty KT et al. (2012) Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 118:6055-6062.
6. Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, and Dent P (2012) Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Mol Pharmacol 82:1217-1229.
7. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, and McNabola A et al. (2007) Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25:3766-3773. (Pubitemid 47372619)
8. Fulda S (2013) Modulation of mitochondrial apoptosis by PI3K inhibitors. Mitochondrion 13:195-198.
9. Gollob JA, Wilhelm S, Carter C, and Kelley SL (2006) Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33:392-406. (Pubitemid 44142735)
10. Gores GJ and Kaufmann SH (2012) Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 26:305-311.
11. Gwak HS, Shingu T, Chumbalkar V, Hwang YH, DeJournett R, Latha K, Koul D, Alfred Yung WK, Powis G, and Farrell NP et al. (2011) Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int J Cancer 128:787-796.
12. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S, and Libra M(2012) Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol 40:639-644.
13. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, and Eckhardt SG et al. (2012) A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18 :4173-4182.
14. Ibrahim N, Yu Y, Walsh WR, and Yang JL (2012) Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). review Oncol Rep 27:1303-1311.
15. Ihle NT, Lemos R, Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, and Powis G (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-150.
16. Kim SH, Ricci MS, and El-Deiry WS (2008) Mcl-1: a gateway to TRAIL sensitization. Cancer Res 68:2062-2064. (Pubitemid 351521775)
17. Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, and Carlo-Stella C (2013) Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia [Epub ahead of print].
18. Matsuda Y and Fukumoto M (2011) Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 44:183-189.
19. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, and Liu X et al. (2008) Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 7:1648-1662.
20. Rahmani M, Davis EM, Bauer C, Dent P, and Grant S (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves downregulation of Mcl-1 through inhibition of translation. J Biol Chem 280:35217-35227. (Pubitemid 41532709)
21. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, and Grant S (2007) The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27:5499-5513. (Pubitemid 47124402)
22. Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, and Grant S (2009) The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 114:4507-4516.
23. Rahmani M, Aust MM, Attkisson E, Williams DC, Jr, Ferreira-Gonzalez A, and Grant S (2013) Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res 73:1340-1351.
24. Rodon J, Dienstmann R, Serra V, and Tabernero J (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10:143-153.
25. Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, and Dormond O (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer 10:90.
26. Sancho-Martinez I and Martin-Villalba A (2009) Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 8:838-842.
27. Sheridan C, Brumatti G, and Martin SJ (2008) Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem 283:22128-22135.
28. Sun H, Wang Z, Yakisich JS. (2012) Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents. Anticancer Agents Med Chem [Epub ahead of print].
29. Yacoub A, Liu R, Park MA, Hamed HA, Dash R, Schramm DN, Sarkar D, Dimitriev IP, Bell JK, and Grant S et al. (2010) Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol 77:298-310.
30. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, and Lee R et al. (2008) Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 14: 5385-5399.